Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells
Open Access
- 22 February 2022
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (2) , 1-11
Abstract
Despite favorable responses to initial chemotherapy, drug resistance is a major cause limiting chemotherapeutic efficacy in many advanced cancers. However, mechanisms that drive drug-specific resistance in chemotherapy for patients with advanced cancers are still unclear. Here, we report a unique role of death-associated protein kinase-related apoptosis-inducing kinase 1 (DRAK1) associated with paclitaxel resistance in cervical cancer cells. Interestingly, DRAK1 protein level was markedly decreased in paclitaxel-resistant cervical cancer cells without affecting its mRNA expression, which resulted in an increase in tumor necrosis factor receptor-associated factor 6 (TRAF6) expression, as well as an activation of TRAF6-mediated nuclear factor-kappa B (NF-κB) signaling cascade, thereby promoting tumor progression. DRAK1 depletion markedly increased the chemotherapeutic IC50 values of paclitaxel in cervical cancer cells. Ectopic expression of DRAK1 inhibited growth of paclitaxel-resistant cervical cancer cells in vitro and in vivo. Furthermore, DRAK1 was markedly underexpressed in chemoresistant cervical cancer patient tissues compared with chemosensitive samples. We found that DRAK1 protein was destabilized through K48-linked polyubiquitination promoted by the Cullin scaffold protein 3 (CUL3) / speckle-type POZ (poxvirus and zinc finger protein) protein (SPOP) E3 ubiquitin ligase in paclitaxel-resistant cells. Collectively, these findings suggest that DRAK1 may serve as a potential predictive biomarker for overcoming paclitaxel resistance in cervical cancer.Keywords
Funding Information
- Ministry of Health and Welfare (HA17C0037, HA17C0037)
This publication has 42 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancerJournal of Clinical Investigation, 2011
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Serine/Threonine Kinase 17A Is a Novel p53 Target Gene and Modulator of Cisplatin Toxicity and Reactive Oxygen Species in Testicular Cancer CellsJournal of Biological Chemistry, 2011
- Long-term prognosis in stable angina; medical treatment or coronary revascularization in patients younger than 70years?International Journal of Cardiology, 2011
- The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responsesThe EMBO Journal, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHPAnti-Cancer Drugs, 2007
- Nuclear factor-κB inhibitors as sensitizers to anticancer drugsNature Reviews Cancer, 2005
- Paclitaxel for non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2004